Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
embridge: Empasiprubart + IVIg in Guillain-Barré Syndrome
NCT07821762Phase 2Not yet recruiting
- Sponsor
- argenx
- Start
- Dec 2026
- Primary completion
- Jan 2028
01
Overview
A Phase 2 trial of empasiprubart in Guillain-Barré syndrome (GBS), sponsored by argenx. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
empasiprubart
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT07821762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07821762.